to-the-point
New Retina Radio
Episode 51

ARCHWAY at AAO

The Port Delivery System With Ranibizumab (Genentech) is under investigation for the treatment of wet AMD in the phase 3 ARCHWAY trial, data from which was shared at this year's AAO Annual Meeting. Nancy Holekamp, MD, sits down with NRR to provide a primary analysis of the results of ARCHWAY and discusses safety outcomes.

11/18/2020 | 14:08

More Episodes: